Paradigm 2 is a multi-centre, blinded study designed to assess the safety and efficacy of the glycopegylated recombinant factor IX as on-demand or prophylactic treatment against haemophilia B.
The app enables to share large data sets in Illumina’s BaseSpace cloud, where they can easily be reviewed and included in Elsevier’s open access journal, Genomics Data. The
As per the terms of the agreement, BASF will use Dyadic’s patented and proprietary C1 platform technology to develop, manufacture, distribute and sell industrial enzymes in certain fields
As per the extension agreement, Galapagos will fund and complete a Phase 2 program in Crohn’s disease, which is designed to facilitate rapid progression into Phase 3. AbbVie
Neucardin is a genetically engineered recombinant peptide fragment of neuregulin-1 that is used as a therapeutic drug to treat advanced chronic heart failure (CHF). As per the terms
DCVax-L mobilizes a cancer patient’s whole immune system to attack the full set of biomarker targets on the tumour. King’s College Hospital neuro-oncology lead and consultant neurosurgeon Dr.
Almac and the departments of Biochemical Engineering and Chemistry at UCL are set to complete the R&D work with high level input from professors John Ward and Helen
The safety and tolerability profile of single ascending doses of TTI-1612 will be assessed in the study. Stem Cell Therapeutics chief scientific officer Dr. Bob Uger said, "We
The new anti-bacterial agents will be based on a highly validated target family involved in bacterial cell wall biosynthesis. Evotec CEO Dr Werner Lanthaler said, "The lack of
The product is presently in the development stage for the treatment of chemotherapy-induced nausea and vomiting (CINV). As per the terms of the deal, Vifor Pharma will not
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.